Evidence map›Paper›PMID 40486433›Full record

ArticleCureus2025

Visceral Perforation Following Hemostatic Powder TC-325 Application in a Patient With Gastric Cancer: A Case Report.

Konstantinos Papantoniou, Theodora Kafentzi, Christos Sotiropoulos, Konstantinos C Thomopoulos, Christos Konstantakis

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Konstantinos PapantoniouDepartment of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.
Theodora KafentziDepartment of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.
Christos SotiropoulosDepartment of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.
Konstantinos C ThomopoulosDepartment of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.
Christos KonstantakisDepartment of Internal Medicine, Division of Gastroenterology, Patras Medical School, University of Patras, Patras, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant tumors of the upper gastrointestinal (GI) tract are a common cause of GI bleeding, often presenting therapeutic challenges due to diffuse hemorrhage and poor visualization. Local hemostatic agents, such as TC-325 (Hemospray; Winston-Salem, NC: Cook Medical), have emerged as effective bridging therapies prior to definitive treatment. However, visceral perforation, though rare, is a serious complication associated with TC-325 use. We present a case of an 87-year-old male with metastatic gastric adenocarcinoma who experienced visceral perforation following TC-325 application for recurrent upper GI bleeding. Despite achieving initial hemostasis, the patient succumbed to complications of perforation. This study highlights the need for caution when using TC-325 in patients with advanced malignancies and friable tissue.

Indexed as

bleedingendoscopyhemostasismalignancyperforationtc-325

Identifiers

PMID40486433
PMCPMC12141772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.